EGFR Polymorphism of the Kinase Domain in Japanese Lung Cancer

Sasaki, Hidefumi; Endo, Katsuhiko; Takada, Minoru; Kawahara, Mutsuto; Tanaka, Hatsukazu; Kitahara, Naoto; Matsumura, Akira; Iuchi, Keiji; Kawaguchi, Tomoya; Okuda, Kunio; Kawano, Osamu; Yukiue, Haruhiro; Yokoyama, Takehito; Yano, Motoki; Fujii, Yoshitaka

doi:10.1016/j.jss.2007.09.001

Cited by 17 publications

(19 citation statements)

References 23 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The Q787Q EGFR polymorphism was detected in 83.6% of all lung cancer patients in the Caucasian population [17] and 28.3% of Japanese NSCLC patients [18]. Similarly to the Japanese study, our results showed that the Q787Q EGFR polymorphism was detected in 23.9% of all NSCLC patients.…”

Section: Discussionsupporting

confidence: 80%

“…Moreover, the Q787Q EGFR polymorphism was shown to be a prognostic biomarker for lung squamous cell carcinomas; however, the same was not shown for lung adenocarcinomas. The Q787Q EGFR polymorphism was also shown to be significantly correlated with the pathological subtype of nonadenocarcinoma in a previous study [18]. The discrepancy between the Q787Q EGFR polymorphism and other common EGFR mutations suggests that the pathogenesis of lung cancers arising in males and heavy smokers is different than that of female and non-/light smokers.…”

Section: Discussionmentioning

confidence: 94%

“…Among patients treated with gefitinib, it was found that those with wild-type EGFR had a better prognosis than those with the Q787Q EGFR polymorphism [18]. It was also reported that one patient with the Q787Q EGFR polymorphism did not respond to gefitinib therapy [42].…”

Section: Discussionmentioning

confidence: 99%

“…A previous case-control study revealed that cases with a polymorphism at nucleotide 2607 in EGFR exon 20 (G2607A; Q787Q; rs 10251977) are more susceptible to lung cancer [17]. In patients treated with gefitinib, there was a tendency toward a poorer prognosis for the group with the Q787Q EGFR polymorphism than for the group with the EGFR wild type [18]. Furthermore, the Q787Q EGFR polymorphism was frequently detected in nonadenocarcinoma lung cancer.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Q787Q EGFR Polymorphism as a Prognostic Factor for Lung Squamous Cell Carcinoma

Koh

Kim²,

Kwon³

et al. 2016

Oncology

View full text Add to dashboard Cite

Objective: EGFR genetic polymorphisms have been investigated for carcinogenesis in various tumors including lung cancer. We evaluated EGFR mutations in four exons, with an emphasis on the Q787Q EGFR polymorphism in non-small-cell lung cancer. Methods: To determine the presence of the Q787Q polymorphism in patients with lung cancer, we performed direct sequencing analyses of four exons for 83 squamous cell carcinomas and 80 adenocarcinomas untreated with EGFR tyrosine kinase inhibitors. Results: The Q787Q EGFR polymorphism was more frequently detected in squamous cell carcinoma patients than in adenocarcinoma patients (24 vs. 15.9%). The group of patients with the Q787Q EGFR polymorphism included more males and heavy smokers compared with other patient groups. The presence of the Q787Q EGFR polymorphism significantly and negatively affected the overall survival rate among patients with non-small-cell carcinoma (p = 0.011), particularly those with squamous cell carcinoma (p = 0.037). Among stage I and II squamous cell carcinoma patients, those with the Q787Q EGFR polymorphism had a poor prognosis (p = 0.032). Conclusions: The Q787Q EGFR polymorphism allows stratifying lung squamous cell carcinoma patients and could be an independent prognostic marker, particularly among those in stages I and II.

show abstract

Section: Discussionsupporting

confidence: 80%

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Q787Q EGFR Polymorphism as a Prognostic Factor for Lung Squamous Cell Carcinoma

Koh

Kim²,

Kwon³

et al. 2016

Oncology

View full text Add to dashboard Cite

show abstract

“…It is still a serious malignancy in many cases due to the lack of major advancements in treatment strategy. 1 Current treatments for lung cancer have shown little success because they cannot cure disseminated tumors with an acceptable level of toxicity. Thus, one alternative strategy that has shown promise in the treatment of lung cancer is targeted therapy.…”

Section: Introductionmentioning

confidence: 99%

Lactoferrin-Conjugated Dendritic Nanoconstructs for Lung Targeting of Methotrexate

Kurmi

Gajbhiye

Kayat

et al. 2011

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients

et al. 2015

View full text Add to dashboard Cite

Genetic factors are known to affect the efficiency of therapy with monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR) in patients with metastatic colorectal cancer (mCRC). At present, the only accepted molecular marker predictive of the response to anti-EGFR mAbs is the somatic mutation of KRAS and NRAS as a marker of resistance to anti-EGFR. However, only a fraction of KRAS wild-type patients benefit from that treatment. In this study, we show that the EGFR gene polymorphism rs1050171 defines, independently of RAS mutational status, a sub-population of 11 % of patients with a better clinical outcome after anti-EGFR treatment. Median PFS for patients with the GG genotype was 10.17 months compared to 5.37 of those with AG + AA genotypes. Taken together, our findings could be used to better define CRC populations responding to anti-EGFR therapy. Further studies in larger independent cohorts are necessary to validate the present observation that a synonymous polymorphism in EGFR gene impacts on clinical responsiveness.

show abstract

EGFR Polymorphism of the Kinase Domain in Japanese Lung Cancer

Cited by 17 publications

References 23 publications

Q787Q EGFR Polymorphism as a Prognostic Factor for Lung Squamous Cell Carcinoma

Q787Q EGFR Polymorphism as a Prognostic Factor for Lung Squamous Cell Carcinoma

Lactoferrin-Conjugated Dendritic Nanoconstructs for Lung Targeting of Methotrexate

A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients

Contact Info

Product

Resources

About